The FDA told MEDVi that its site falsely suggested MEDVi was the compounder of the semaglutide and tirzepatide it sold, and that claims like Same active ingredient as Wegovy and Ozempic and Same active ingredient as Mounjaro and Zepbound falsely implied FDA approval or evaluation

While these drugs are highly effective for weight loss and glycemic control, they are associated with gastrointestinal issues such as nausea, vomiting, and diarrhea, which can lead to treatment discontinuation among some patients For instance, clinical data and patient reports have shown that adverse events are particularly common during the early stages of treatment with drugs such as semaglutide and tirzepatide, prompting careful dose titration and medical supervision, which may not be feasible for all patients or healthcare settings Addressing these side effect concerns through better patient education, physician training, and next-generation formulations with reduced tolerability issues is crucial to improving long-term adherence and treatment outcomes
Tirzepatide's added GIP activity appears to further enhance fat metabolism and reduce food intake, which is the leading theory for why it tends to outperform semaglutide on weight loss
Extending its duration of action has become a focus of drug development
Readers evaluating these outcomes should note that the REDEFINE readouts describe the combination product